Business
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for locally treatable infectious diseases called the Bisphosphocin® class, today announced that it has entered into an agreement with Professional Education and Research Institute LLC (PERI) to serve as the contract research organization (CRO) for its upcoming Phase 2 clinical program of Nu-3, the Company's lead Bisphosphocin®
About this update from Lakewood-amedex Biotherapeutics Inc.
[{"type":"text","content":"Specialized CRO partnership supports Phase 2 program to advance Nu-3 toward potential registration pathway in large, underserved iDFU market","length":140,"tagName":"p"},{"type":"text","content":"SARASOTA, Fla., May 12, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for locally treatable infectious diseases called the Bisphosphocin® class, today announced that it has entered into an agreement with Professional Education and Research Institute LLC (PERI) to serve as the contract research organization (CRO) for its upcoming Phase 2 clinical program of Nu-3, the Company's lead Bisphosphocin® product for the treatment of mildly infected diabetic foot ulcers (iDFU). Nu-3 belongs to a novel class of antimicrobials (Bisphosphocin®) possessing a unique mechanism of action that enables rapid elimination of a broad spectrum of bacteria, including resistant pathogens and biofilms, based on available non-clinical in vitro and in vivo data.","length":899,"tagName":"p"},{"type":"image","alt":"Lakewood-Amedex Biotherapeutics Inc. (PRNewsfoto/Lakewood-Amedex Biotherapeutics Inc.)","displaySize":"","headline":null,"caption":"Lakewood-Amedex Biotherapeutics Inc. (PRNewsfoto/Lakewood-Amedex Biotherapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":265,"url":"https://media.zenfs.com/en/prnewswire.com/fdc26168a77475cab607f9d367d14d43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/blfhaGRBqtvusCvNb93wvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ2Nw--/https://media.zenfs.com/en/prnewswire.com/fdc26168a77475cab607f9d367d14d43","width":400,"height":265},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Whfo5bcFUcQ2gj0XvWCiHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQyNA--/https://media.zenfs.com/en/prnewswire.com/fdc26168a77475cab607f9d367d14d43","width":400,"height":265}},"href":"https://mma.prnewswire.com/media/2618352/Lakewood_Amedex_Biotherapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The selection of PERI reflects strategic alignment with a CRO that has a strong track record in wound care and podiatric medicine. Founded by Charles Zelen, DPM, FACFAS, a practicing podiatrist with deep ties to the diabetic foot c...